Treatment of established postoperative nausea and vomiting: a quantitative systematic review.

BACKGROUND: The relative efficacy of antiemetics for the treatment of postoperative nausea and vomiting (PONV) is poorly understood.
METHODS: Systematic search (MEDLINE, Embase, Cochrane Library, bibliographies, any language, to 8.2000) for randomised comparisons of antiemetics with any comparator for the treatment of established PONV. Dichotomous data on prevention of further nausea and vomiting, and on side effects were combined using a fixed effect model.
RESULTS: In seven trials (1,267 patients), 11 different antiemetics were tested without placebos; these data were not further analysed. Eighteen trials (3,809) had placebo controls. Dolasetron 12.5-100 mg, granisetron 0.1-3 mg, tropisetron 0.5-5 mg, and ondansetron 1-8 mg prevented further vomiting with little evidence of dose-responsiveness; with all regimens, absolute risk reductions compared with placebo were 20%-30%. The anti-nausea effect was less pronounced. Headache was dose-dependent. Results on propofol were contradictory. The NK1 antagonist GR205171, isopropyl alcohol vapor, metoclopramide, domperidone, and midazolam were tested in one trial each with a limited number of patients.
CONCLUSIONS: Of 100 vomiting surgical patients receiving a 5-HT3 receptor antagonist, 20 to 30 will stop vomiting who would not have done so had they received a placebo; less will profit from the anti-nausea effect. There is a lack of evidence for a clinically relevant dose-response; minimal effective doses may be used. There is a discrepancy between the plethora of trials on prevention of PONV and the paucity of trials on treatment of established symptoms. Valid data on the therapeutic efficacy of classic antiemetics, which have been used for decades, are needed.

Introduction

Postoperative nausea and vomiting (PONV) are among the most common adverse events after surgery and anaesthesia. Compared with other postoperative complications (for instance, wound infection, deep vein thrombosis or myocardial ischemia), PONV is of minor medical importance; it almost never kills, and it never becomes chronic. However, PONV may be very distressing for patients. Workload for nursing staff dealing with vomiting patients is increased. In ambulatory surgery, intractable PONV may lead to unanticipated hospital admission.

In France, 10% percent of the population underwent an anaesthetic procedure in 1996 [1]. On average 30% of patients are suffering from PONV symptoms [2], and 1% of surgical outpatients need to be admitted to hospital due to intractable PONV [3-5]. Extrapolating these numbers to the UK suggests that every year almost 2'000'000 people suffer from PONV symptoms, and about 20'000 outpatients need to be admitted following ambulatory surgery due to intractable PONV. Thus, PONV is likely to create considerable extra costs for health care systems.

Much research on the control of PONV has been conducted during the last four decades. The majority of clinical trials focuses on prophylaxis of PONV (i.e. patients receive an antiemetic at induction of anaesthesia, during surgery or shortly before they wake up). There are, however, several problems with the prevention of PONV. First, the efficacy of prophylactic antiemetic interventions in the daily surgical setting (i.e. when the baseline risk for PONV is not particularly high) is often disappointing [2]. Second, there is no evidence that prophylaxis decreases the likelihood of unanticipated admission [2]. Third, prophylaxis of PONV is likely to be less cost-effective than treatment of established symptoms [6]. And finally, with prevention strategies, patients who actually do not need any prophylaxis are unnecessarily exposed to a drug, and are thus put at risk of suffering from unnecessary adverse drug reactions.

Efficacious and safe treatment strategies for patients who are nauseated or who are vomiting after surgery are needed. The aim of this study was to systematically review the literature on valid data on any treatment of established PONV symptoms, to critically appraise the data, to test for dose-responsiveness for each drug, and to estimate relative efficacy and likelihood for harm of the various treatments.

Methods

Systematic search

We searched the MEDLINE (PubMed, from 1966), and EMBASE (from 1974) databases using different search strategies. We also searched the Cochrane Controlled Trials Register (Cochrane Library 2000, issue IV). We used the free text terms (postoperative OR postoperative OR postsurg*), (nausea OR vomiting OR emesis OR retching), (randomised OR randomized), (treatment), NOT (chemotherapy OR radiotherapy), NOT (prevention OR prophylaxis) and combinations of these terms. The date of the last electronic search was 21.8.2000. We checked reference lists of retrieved reports and relevant review articles, and we searched our own comprehensive in-house bibliography. Authors of original trials were contacted when there was ambiguity about the data. We did not contact manufacturers.

Inclusion and exclusion criteria, validity assessment, data extraction

We included full reports of randomised comparisons of any therapeutic antiemetic intervention (experimental intervention) with placebo, no treatment or another antiemetic (control intervention) in vomiting or nauseated postoperative patients. When Intralipid® was used as a control in propofol trials (to maintain blinding due to its milky-white colour), it was considered as an inactive control.

Retrieved reports were screened by one author (FK). Reports, which did not clearly meet inclusion criteria were excluded at this stage. All potentially relevant reports were then read by all authors independently who scored them for methodological validity using the three-item, five point Oxford scale taking into account randomisation, double-blinding, and description of withdrawals [7]. The minimum validity requirement for an included trial was an adequate method of randomisation (for instance, a table of random numbers). Trials with pseudo-randomisation (for instance, according to patients' date of birth) were excluded.

The main endpoint of efficacy was a "success" (i.e. no further nausea or vomiting in a nauseated or vomiting patient). According to previous analyses [8], and in agreement with the majority of all retrieved trials, we distinguished between two arbitrarily defined observations periods: "early success" was within or close to 6 hours after administration of the study drugs, and "late success" was within or close to 24 hours. Dichotomous data on anti-vomiting and anti-nausea efficacy were separately extracted, and separately analysed. When no distinction was made between nausea and vomiting, the data were not further analysed. Data on adverse drug reactions were analysed when they were reported in dichotomous form. Data on patients' satisfaction, duration of hospital stay, number of vomiting episodes, degree of nausea, or number of rescue treatments were not analysed since these data were inconsistently reported. Sponsorship was assumed when it was acknowledged in the original paper or when a representative of the manufacturer was a co-author of the paper. All data were extracted by one author (FK) and then checked by the two others independently. Authors met to agree consensus on validity scores and extracted data; discrepancies were resolved by discussion.

Analyses

For both efficacy and harm we calculated relative risks with 95% confidence intervals [9]. A statistically significant difference between an experimental intervention and control was assumed when the 95% confidence interval around the relative risk did not include 1. Data from independent trials were combined only when the data represented clinically homogenous subgroups. Such subgroups would include comparisons of data of the same dose and route of administration of the same experimental intervention, with the same control intervention (for instance, a placebo), and reporting on the same emesis endpoint (for instance vomiting) during the same observation period (for instance late success). A fixed effect model was used to combine these clinically homogenous data [10].

It became clear that valid trials represented homogenous patient populations with minimal variations in baseline risks and outcome frequencies. Also, most antiemetic interventions were tested in one or two large multicentre studies with similar control event rates. As estimates of the clinical relevance of the antiemetic efficacy of the treatments, we, therefore, calculated absolute risk reductions compared with placebo. We also calculated the reciprocal of the absolute risk reduction, the number-needed-to-treat [11], with 95% confidence interval [12].

Dose-responsiveness was tested for as with previous similar analyses [8,13], taking into account criteria of both statistical significance and clinical relevance of differences in efficacy between doses. Since control event rates were very similar in these trials, we were using the absolute risk reduction (and the number-needed-to-treat) to test for dose-responsiveness. For homogeneous subgroups, absolute risk reductions (numbers-needed-to-treat) were graphically plotted as recently suggested [14]. A consistent increase in the absolute risk reduction (a decrease in the number-needed-to-treat) with increasing doses was interpreted as weak evidence of dose-responsiveness. A statistically significant difference between two doses, and thus strong evidence of dose-responsiveness, was assumed when the 95% confidence intervals of the absolute risk reductions (numbers-needed-to-treat) of these two doses did not overlap, or when the higher dose was significantly different from control and the lower dose was not. According to a pre-hoc decision in the clinical setting of PONV [15], a change of the absolute risk reduction by • 20% was regarded as a clinically relevant degree of change in antiemetic efficacy. For instance, a decrease of the number-needed-to-treat from 5 to 4 compared with placebo to prevent further vomiting in a vomiting patient by increasing the dose would be regarded as a worthwhile improvement. This would then justify an increase of the dose [8,13].

Results

Included and excluded articles

We screened 55 reports; 34 of those were potentially relevant for the purpose of this study (Figure 1). Nine had to be subsequently excluded. Data of one large sponsored multicentre trial on ondansetron (500 patients) [16] were published in two further full reports [17,18], and data of one large sponsored multicentre trial on dolasetron (620 patients) [19] were published in one subsequent full report [20]; the original reports only were considered by us [16,19]. In two trials, treatment allocation was not randomised; one tested ondansetron [21], the other pepermint oil [22]. In two trials, patients received both prophylactic and therapeutic antiemetic interventions, and efficacy data could not been separated; one trial tested droperidol and metoclopramide [23], the other droperidol, metoclopramide, and domperidone [24]. One trial did not report on efficacy data which were relevant for the purpose of this analysis [25]. Finally, one report was on patients with nausea and vomiting due to oesophageal and gastric disorders [26].

Figure 1

Flowchart of retrieved and analysed reports.

Twenty-five trials fulfilled our inclusion criteria. One on domperidone was published in 1980 [27], all others were published after 1990; 11 trials (44%) were published since 1997. One report was in German [28] all others were in English. Three trials were in children [29-31], all others were in adults. In the 17 trials, which reported on the number of patients who were followed up before randomisation, 12,107 patients were followed up and 3,572 of those vomited or felt nauseous before treatment (average 30%, range 9% [32] to 63% [33]). We contacted the main authors of two trials to clarify inconsistencies in the reporting of late success data [34,35]. One author only responded to our enquiry [34]; these data were included in our analyses.

Active controlled trials

In seven randomised trials (1,267 patients) [28,29,32,36-39], eleven different experimental interventions were tested without a placebo group (Table 1). One antiemetic intervention was tested in three trials, five in two each, and five in one each. Because of the large variety in different experimental interventions and the inconsistency in control interventions, these data were not further analysed.

Table 1

Active-controlled trials

Ref	Validity score	Comparison	Surgery	Sponsorship
	random blinding dropouts	(number of patients in brackets)
[28]	1/1/0	1) Ondansetron 8 mg iv (50) 2) Droperidol 1.25 mg iv (50)	Not reported
[29]	2/2/1	1) Ondansetron 0.1 mg/kg iv (16) 2) Droperidol 20 μg/kg iv (13)	Extraabdominal
[32]	2/2/0	1) Droperidol 1.25 mg iv (27) 2) Metoclopramide 10 mg iv (25) 3) Propofol 10 mg iv (26)	Mixed
[36]	1/1/0	1) Ondansetron 4 mg iv (380) 2) Metoclopramide 10 mg iv (366)	Not reported	Glaxo
[37]	1/1/0	1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40)	Laparoscopic cholecystectomy
[38]	1/1/0	1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40)	Major gynecological
[39]	1/1/1	1) Alizapride 100 mg iv (24) 2) Droperidol 1 mg iv (25) 3) Ondansetron 8 mg iv (25)	Gynecological	Glaxo

Placebo controlled trials

In 18 trials (3,809 patients), there was an inactive control group [16,17,19,27,30,31,33-35,40-48] (Table 2). Most trials reported separately on anti-nausea and anti-vomiting data. Three trials also reported on combined nausea and vomiting data [33-35], and two (one tested ondansetron and metoclopramide [45], and one tested domperidone [27]) reported only on combined data. Combined data were not further analysed.

Table 2

Placebo-controlled trials

Ref	Validity score	Comparison	Surgery	Early success			Late success			Sponsorship
					absence of			absence of
	random blinding dropouts	(number of patients in brackets)		time point	nausea	vomiting	time point	nausea	vomiting
Dolasetron
[40]	1/1/0	1) Dolasetron 12.5 mg iv (66) 2) Dolasetron 25 mg iv (65) 3) Dolasetron 50 mg iv (67) 4) Dolasetron 100 mg iv (68) 5) Placebo iv (71)	Mixed		no data		24 h	no data	16/66 18/65 25/67 17/68 8/71	Hoechst Marion Russel
[19]	2/1/0	1) Dolasetron 12.5 mg iv (130) 2) Dolasetron 25 mg iv (119) 3) Dolasetron 50 mg iv (124) 4) Dolasetron 100 mg iv (126) 5) Placebo iv (121)	Mixed	2 h	no data	72/130 60/119 60/124 64/126 33/121	24 h	no data	46/130 33/119 36/124 37/126 13/121	Hoechst Marion Russel
Granisetron
[41]	2/1/1	1) Granisetron 0.1 mg iv (128) 2) Granisetron 1 mg iv (133) 3) Granisetron 3 mg iv (125) 4) Placebo iv (133)	Mixed	6 h	51/128 54/133 53/125 22/133	68/128 77/133 75/125 35/133	24 h	34/128 40/133 46/125 17/133	49/128 61/133 61/125 26/133
Tropisetron
[34]	1/2/0	1) Tropisetron 0.5 mg iv (77) 2) Tropisetron 2 mg iv (80) 3) Tropisetron 5 mg iv (80) 4) Placebo iv (77)	Mixed	4 h	45/77 45/80 45/80 35/77	54/77 61/80 59/80 35/77	24 h	33/77 36/80 37/80 26/77	40/77 46/80 48/80 22/77	Sandoz
Ondansetron
[42]	2/2/0	1) Ondansetron 8 mg iv (35) 2) Placebo iv (36)	Laparoscopy	2 h	no data	17/35 3/36		no data		Glaxo
[17]	1/1/1	1) Ondansetron 1 mg iv (112) 2) Ondansetron 4 mg iv (112) 3) Ondansetron 8 mg iv (104) 4) Placebo iv (108)	Not specified		no data		24 h	no data	45/112 49/112 43/104 28/108	Glaxo
[16]	1/1/0	1) Ondansetron 1 mg iv (130) 2) Ondansetron 4 mg iv (119) 3) Ondansetron 8 mg iv (122) 4) Placebo iv (129)	Mixed	2 h	no data	74/130 73/119 70/122 39/129	24 h	no data	53/130 56/119 57/122 19/129	Glaxo
[30]	2/2/1	1) Ondansetron 0.1 mg/kg iv (192) 2) Placebo iv (183)	Paediatric	2 h	no data	150/192 63/183	24 h	no data	98/186 30/179	Glaxo
[44]	2/1/0	1) Ondansetron 8 mg iv (18) 2) Placebo iv (18)	Mixed	4 h	14/18 5/18	17/18 17/18		no data		Glaxo
[45]	1/1/1	1) Ondansetron 4 mg iv (58) 2) Metoclopramide 10 mg iv (57) 3) Placebo iv (60)	Gynaecologic laparoscopy	0.5 h	Only combined nausea+vomiting data		48 h	Only combined nausea+vomiting data
[43]	2/2/0	1) Ondansetron 0.1 mg iv (32) 2) Ondansetron 4 mg iv (29) 3) Ondansetron 16 mg iv (28) 4) Placebo iv (32)	Mixed	6 h	no data	7/32 12/29 15/28 5/32	24 h	no data	5/32 11/29 14/28 5/32	Glaxo
Propofol
[35]	1/2/0	1) Propofol 20 mg iv (24) 2) Propofol 40 mg iv (22) 3) Intralipid iv (23)	Day case	2 h	no data	21/24 17/22 13/23	no data
[46]	1/1/0	1) Propofol 3 mg iv (12) 2) Propofol 9 mg iv (12) 3) Propofol 27 mg iv (12) 4) Intralipid iv (12)	Gynecologic laparoscopy	1.5 h	4/12 3/12 3/12 3/12	10/12 11/12 7/12 10/12	no data			ICI Pharmaceuticals
[47]	2/1/0	1) Propofol 0.2 mg/kg iv (35) 2) Intralipid (35)	Adenectomy Tonsillectomy	1 h	no data	34/35 30/35	24 h	no data	13/35 20/35
Others
[48]	2/2/0	1) Midazolam 1 mg iv + 1 mg/h (10) 2) Placebo iv (10)	Any surgery	9 h	no data	9/10 3/10	no data
[33]	1/1/0	1) GR205171 25 mg iv (18) 2) Placebo iv (18)	Hysterectomy	2 h	10/18 4/18	14/18 5/18	24 h	Only combined nausea+vomiting data		Glaxo
[27]	1/1/0	1) Domperidone 10 mg iv (52) 2) Placebo iv (48)	Mixed	6 h	Only combined nausea+vomiting data		no data
[31]	2/0/0	1) Isopropyl alcohol vapor nasal (20) 2) Saline nasal (19)	Paediatric	1 h	18/20 8/19	7/20 2/19	no data

All trials are in adults, except "paediatric"

Eleven trials (61% of all placebo-controlled trials) tested four 5-HT3receptor antagonists (dolasetron, granisetron, ondansetron, or tropisetron) in 3,427 patients (90% of all patients in placebo-controlled trials). Average trial size was 312 patients (range, 36 to 620). Median validity score was 3 (range, 2 to 5). Most data came from multicentre dose-finding studies that were sponsored by the manufacturers of the respective 5-HT3 receptor antagonists.

Three trials tested propofol [35,46,47], and one each midazolam [48], a NK1 antagonist (GR205171) [33], domperidone [27], and isopropyl alcohol vapor [31] in 382 patients. In those trials, average size was 55 patients (range, 20 to 100). This was significantly different from the trials on 5-HT3 receptor antagonists (p = 0.002). Median validity score was 2 (range, 2 to 4). This was not different from trials on 5-HT3 receptor antagonists (p = 0.126). Two trials were sponsored [33,46].

5-HT3 receptor antagonists

Granisetron 0.1 mg, 1 mg, and 3 mg (386 patients received granisetron) and tropisetron 0.5 mg, 2 mg, and 5 mg (237) were tested in one multicentre trial each [34,41]. Dolasetron 12.5, 25 mg, 50 mg, and 100 mg was tested in two multicentre trials (765) [19,40]. Data on ondansetron came from seven trials. Three doses, 1 mg, 4 mg, and 8 mg were tested in 839 adults in two multicentre [16,17] and four single centre trials [42-45], and 0.1 mg and 16 mg were tested in 60 adults in one trial [43]. Finally, 0.1 mg/kg was tested in 192 children in one trial [30]; this was the only paediatric trial that tested a setron.

Graphical display suggested similar anti-vomiting efficacy with all 5-HT3receptor antagonists, and little evidence of dose-responsiveness (Table 3, Figure 2). For early success, relative risk point estimates were between 1.6 and 2.2, and numbers-needed-to-treat point estimates were between 3.0 and 4.7. According to our predefined criteria, there was some evidence of dose-responsiveness with ondansetron; the lowest dose tested, 0.1 mg, was no different from placebo, and all higher doses were significantly more efficacious than placebo. With the main fixed doses (1 mg, 4 mg, and 8 mg), however, there was no clinically relevant dose-response; the number-needed-to-treat for late anti-vomiting efficacy decreased from 4.8 to 4.1 (i.e. an improvement by 15%). Best anti-vomiting efficacy was with granisetron, and there was some evidence of a clinically relevant dose-response. With the lowest dose tested (0.1 mg), the number-needed-to-treat for early success was 3.7. This number decreased to 3.2 (i.e. an improvement by 14%) when the dose was increased by a factor of 10 (to 1 mg). When the dose was further increased by a factor of 30 (to 3 mg), the number-needed-to-treat decreased to 3.0 (i.e. an improvement by 23%). For late success, the improvement was 11% and 36%, when the dose was increased to 1 mg and 3 mg, respectively. There was also some evidence of a clinically relevant dose-response for late anti-vomiting efficacy with tropisetron. With 0.5 mg, the number-needed-to-treat to prevent further vomiting for 24 hours was 4.3. When the dose was increased fourfold, the number-needed-to-treat decreased to 3.5 (i.e. an improvement by 18%). When the dose was increased tenfold, the number-needed-to-treat decreased to 3.2 (i.e. an improvement by 26%).

Table 3

Efficacy data

	Early success					Late success
	Success rate		Relative Risk	Number Needed To Treat	Ref	Success rate		Relative Risk	Number Needed To Treat	Ref
	Active	Control*	(95% confidence interval)	(95% confidence interval)	Active	Control*		(95% confidence interval)	(95% confidence interval)
Prevention of further nausea
Granisetron
0.1 mg	40%	17%	2.41 (1.56 to 3.73)	4.3 (3.0 to 7.9)	[41]	27%	13%	2.08 (1.22 to 3.53)	7.3 (4.3 to 24)	[41]
1 mg	41%	17%	2.45 (1.59 to 3.79)	4.2 (2.9 to 7.4)	[41]	30%	13%	2.35 (1.41 to 3.93)	5.8 (3.7 to 13)	[41]
3 mg	42%	17%	2.56 (1.66 to 3.95)	3.9 (2.7 to 6.6)	[41]	37%	13%	2.88 (1.75 to 4.75)	4.2 (2.9 to 7.2)	[41]
Tropisetron
0.5 mg	58%	45%	1.29 (0.94 to 1.75)	7.7 (3.5 to -38)	[34]	43%	34%	1.27 (0.85 to 1.90)	11 (4.1 to -16)	[34]
2 mg	56%	45%	1.24 (0.91 to 1.69)	9.3 (3.8 to -21)	[34]	45%	34%	1.33 (0.90 to 1.98)	8.9 (3.8 to -25)	[34]
5 mg	56%	45%	1.24 (0.91 to 1.69)	9.3 (3.8 to -21)	[34]	46%	34%	1.37 (0.93 to 2.03)	8.0 (3.6 to -37)	[34]
Ondansetron
8 mg	78%	28%	2.80 (1.28 to 6.14)	2.0 (1.3 to 4.6)	[44]	no data
Propofol
any dose	36%	25%	1.44 (0.49 to 4.22)	9.0 (2.5 to -5.6)	[46]	no data
Other drugs
GR205171 25 mg	56%	22%	2.50 (0.96 to 6.52)	3.0 (1.6 to 29)	[33]	no data
Isopropyl alcohol	90%	42%	2.14 (1.24 to 3.69)	2.1 (1.4 to 4.5)	[31]	no data
Prevention of further vomiting
Dolasetron
12.5 mg	55%	27%	2.03 (1.46 to 2.82)	3.6 (2.5 to 6.1)	[19]	32%	11%	2.88 (1.83 to 4.54)	4.8 (3.5 to 7.8)	[19][40]
25 mg	50%	27%	1.85 (1.31 to 2.60)	4.3 (2.8 to 9.0)	[19]	28%	11%	2.54 (1.59 to 4.04)	6.0 (4.1 to 11)	[19][40]
50 mg	48%	27%	1.77 (1.26 to 2.50)	4.7 (3.0 to 11)	[19]	32%	11%	2.93 (1.86 to 4.61)	4.8 (3.5 to 7.7)	[19][40]
100 mg	51%	27%	1.86 (1.33 to 2.61)	4.3 (2.8 to 8.5)	[19]	28%	11%	2.54 (1.60 to 4.04)	5.9 (4.1 to 11)	[19][40]
Granisetron
0.1 mg	53%	26%	2.02 (1.45 to 2.80)	3.7 (2.6 to 6.5)	[41]	38%	20%	1.96 (1.30 to 2.95)	5.3 (3.4 to 13)	[41]
1 mg	58%	26%	2.20 (1.60 to 3.03)	3.2 (2.3 to 4.9)	[41]	46%	20%	2.35 (1.59 to 3.47)	3.8 (2.7 to 6.5)	[41]
3 mg	60%	26%	2.28 (1.66 to 3.13)	3.0 (2.2 to 4.5)	[41]	49%	20%	2.50 (1.69 to 3.68)	3.4 (2.5 to 5.5)	[41]
Tropisetron
0.5 mg	70%	45%	1.54 (1.16 to 2.05)	4.1 (2.5 to 10)	[34]	52%	29%	1.82 (1.20 to 2.75)	4.3 (2.6 to 12)	[34]
2 mg	76%	45%	1.68 (1.28 to 2.21)	3.2 (2.2 to 6.1)	[34]	58%	29%	2.01 (1.35 to 3.00)	3.5 (2.3 to 7.1)	[34]
5 mg	74%	45%	1.62 (1.23 to 2.14)	3.5 (2.3 to 7.4)	[34]	60%	29%	2.10 (1.41 to 3.12)	3.2 (2.2 to 6.0)	[34]
Ondansetron
0.1 mg	22%	16%	1.40 (0.50 to 3.95)	16 (4.0 to -7.8)	[43]	16%	16%	1.00 (0.32 to 3.12)	∞ (5.6 to -5.6)	[43]
1 mg	57%	30%	1.88 (1.39 to 2.55)	3.7 (2.6 to 6.6)	[16]	40%	20%	2.04 (1.51 to 2.75)	4.8 (3.5 to 7.9)	[16][17]
4 mg	57%	27%	2.10 (1.58 to 2.79)	3.3 (2.5 to 5.1)	[16][43]	45%	19%	2.29 (1.73 to 3.02)	4.0 (3.0 to 5.7)	[16][17][43]
8 mg	59%	32%	1.84 (1.45 to 2.35)	3.7 (2.7 to 5.8)	[16][42][44]	44%	20%	2.23 (1.66 to 3.00)	4.1 (3.1 to 6.2)	[16][17]
16 mg	54%	16%	3.43 (1.43 to 8.23)	2.6 (1.7 to 6.4)	[43]	50%	16%	3.20 (1.32 to 7.76)	2.9 (1.8 to 8.3)	[43]
0.1 mg/kg	78%	34%	2.27 (1.83 to 2.81)	2.3 (1.9 to 2.9)	[30]	53%	17%	3.14 (2.21 to 4.48)	2.8 (2.2 to 3.7)	[30]
Propofol
any dose	85%	76%	1.18 (1.01 to 1.37)	10 (4.6 to -47)	[35][46][47]	53%	57%	0.88 (0.64 to 1.22)	-26 (7.7 to -4.9)	[35][47]
Other drugs
GR205171 25 mg	78%	28%	2.80 (1.28 to 6.14)	2.0 (1.3 to 4.6)	[33]	no data
Isopropyl alcohol	35%	11%	3.33 (0.79 to 14.0)	4.1 (2 to -174)	[31]	no data
Midazolam	90%	30%	3.00 (1.14 to 7.91)	1.7 (1.1 to 3.8)	[48]	no data

*control = placebo, except in propofol trials where control = intralipid; ∞ = infinity (absolute risk reduction = 0)

Figure 2

Prevention of further postoperative nausea and vomiting with 5-HT3 receptor antagonists. Symbols are absolute risk reductions (ARR) or numbers-needed-to-treat (NNT), respectively, with 95% confidence intervals. Symbol sizes are proportional to the number of analysed patients. White circles: vomiting; grey squares: nausea. ∞ = infinity (ARR = 0). All data are from adults.

Three trials only reported on anti-nausea efficacy; two multicentre trials on granisetron [41] and tropisetron [34], respectively, and one small trial on ondansetron [44] (Table 2). Anti-nausea efficacy was consistently less pronounced, compared with the anti-vomiting efficacy (Table 3, Figure 2). For tropisetron, none of the doses tested achieved a statistically significant anti-nausea effect, neither early nor late.

The most frequently reported adverse effect with 5-HT3 receptor antagonists was headache (Table 4). There was some evidence of dose-responsiveness, although for none of the dose groups tested (i.e. low, medium or high) the result was statistically significant. With the lowest doses, the risk of headache was decreased compared with placebo. With the medium doses, there was equivalence. With the highest doses tested, the risk of headache was increased compared with placebo.

Table 4

Risk of headache with 5-HT3 receptor antagonists

							Number with
	5-HT3 receptor antagonist (mg)				Event rate				Relative risk	References
							headache/Total number
Dose	Dolasetron	Granisetron	Tropisetron	Ondansetron	Active	Placebo	Active	Placebo	95% confidence interval
Low:	12.5	0.1	0.5	1	7.7%	10.4%	41/531	55/531	0.75 (0.51 to 1.10)	[16] [19] [34] [40] [41]
Medium:	25, 50	1	2	4	9.3%	9.3%	71/765	55/591	1.09 (0.78 to 1.52)	[16] [19] [34] [40] [41] [45]
High:	100	3	5	8	13.3%	9.9%	74/556	56/567	1.36 (0.98 to 1.88)	[16] [19] [34] [40] [41] [42]

Doses have been grouped arbitrarily into "low", "medium", and "high"; these groups do not represent equipotent doses.

Propofol

Six different regimens of propofol were tested in three trials, each in a limited number of patients [35,46,47] (Table 2). Results were inconsistent. There was a lack of evidence of any dose-effect, or increased efficacy in particular groups of patients. When the data were combined, there was no evidence of a significant anti-vomiting effect (Table 3). One trial only tested early anti-nausea efficacy [46]; the effect was not statistically significant. In two trials, increased sedation with propofol was reported [35,46]. In one trial, one of 22 patients receiving propofol 40 mg had an episode of apnoea [35].

Others

One trial each tested a NK1-receptor antagonist [33], midazolam [48], domperidone [27], nasal isopropyl alcohol [31], and metoclopramide [45] (Tables 2 and 3). Trials were on a limited number of patients, or reported combined nausea and vomiting success rates only.

None of the trials reported on the number of outpatients who needed to be admitted due to intractable PONV.

Discussion

There are three main results of this systematic review. First, 5-HT3receptor antagonists are efficacious to some extent in preventing further vomiting in a patient who is vomiting after surgery; they show less efficacy in preventing further nausea in a nauseated patient. Second, over wide ranges of doses there is weak evidence only of dose-responsiveness with these drugs. Third, although classic antiemetics (for instance, droperidol or metoclopramide) have been widely used for decades, there is a lack of evidence on their therapeutic efficacy in the postoperative period.

The 5-HT3 receptor antagonists were the most frequently tested drugs. For all of them at least one large and well designed multicentre trial could be retrieved. Thus, for this class of antiemetics, treatment recommendations can be based on strong evidence. There were, however, some methodological problems with these trials. For instance, some of them were published more than once [17,18,20]. Also, there were no reports on direct comparisons of 5-HT3 receptor antagonists. Our analyses had to rely on indirect comparisons from placebo-controlled trials. Finally, for most of these trials, reporting of efficacy data was incomplete. It is important to distinguish between anti-vomiting and anti-nausea efficacy since nausea is not a little vomiting [49]. An antiemetic may well stop further vomiting in a vomiting patient but leave the patient nauseous. For both granisetron and tropisetron, there was consistent evidence that the anti-nausea effect was less pronounced than the anti-vomiting effect. For the other setrons no nausea data were reported. This relative lack of anti-nausea efficacy of 5-HT3 receptor antagonists has been well known from previous analyses on prophylactic ondansetron in the surgical setting [13], and on the antiemetic efficacy of 5-HT3 receptor antagonists in patients undergoing radiotherapy [50]. The selective reporting of anti-vomiting efficacy data in the majority of these trials may lead to a biased perception of the antiemetic efficacy of 5-HT3 receptor antagonists.

To know about dose-responsiveness is important for two reasons. First, when larger doses are not much more efficacious than smaller doses, the smaller doses are likely to be more cost-effective. Second, smaller doses may be less harmful. As in previous analyses, we have chosen a combined approach to test for dose-responsiveness, taking into account graphical display, an estimate of the statistical significance of the difference between doses, and an estimate of the clinical relevance of such a difference. Our aim was to facilitate decision-making using a pragmatic and robust method which is clinically applicable. Thus, the major question whether or not to increase the dose of an antiemetic was mainly based on the clinical relevance of any improvement in efficacy. Therefore, and since these trials represented clinically homogenous data and very similar control event rates, we were using the absolute risk reduction and the number-needed-to-treat, respectively, to test for dose-responsiveness. For none of the setrons there was strong evidence of dose-responsiveness. For ondansetron there was some weak evidence; however, the subthreshold dose (0.1 mg) and the dose that was 160 times higher (16 mg) were tested in a very limited number of patients only.

The lack of a clear dose-response with these 5-HT3 receptor antagonists in the surgical setting is surprising for two reasons. First, wide dose ranges were tested. For dolasetron, the doses differed by a factor of 8, for tropisetron by 10, and for granisetron even by 30. This means that for granisetron, for instance, 30 times more drug costs must be spent to safe an additional 10% of vomiting patients from further vomiting (Table 3). Second, for ondansetron there is evidence from systematic review that the optimal dose to prevent PONV is likely to be 8 mg [13]. For therapeutic purposes, however, 1 mg seems to be as efficacious as higher doses (Table 3, Figure 2). This is interesting both from a pharmacologic and an economic point of view. Pharmacologically, these data suggest that minimal amounts of ondansetron are needed to block 5-HT3 receptors in a vomiting patient, but that much higher doses are needed to block these receptors prophylactically. We do not know if this is a kinetic or a dynamic phenomenon, but we may assume that it applies to all setrons. Economically, this observation is interesting since these drugs are relatively expensive. It may make a difference if all surgical patients (including those who actually will not need an antiemetic) receive prophylactically a high dose of an expensive drug, or if only those who are suffering from PONV symptoms will be treated with a small (but effective) dose of the same drug. The pragmatic clinical message is that with all these tested 5-HT3 receptor antagonists, minimal doses may be used to treat established PONV symptoms, while much higher doses are needed to try to prevent these symptoms. Obviously, with the treatment strategy, a patient will have to vomit first or suffer some degree of nausea before she gets a rescue medication.

Headache is a well known adverse effect of 5-HT3 receptor antagonists [13,50]. With the highest doses of all four 5-HT3 receptor antagonists, the risk of headache compared with placebo was increased (although not statistically significant). This may be regarded as a further argument to use minimal effective doses of these drugs. None of the other well known adverse effects of 5-HT3 receptor antagonists, elevated liver enzymes or constipation [13,50], have been reported in more than one trial.

A final issue relates to the lack of valid data on the therapeutic efficacy of the classic antiemetics in the postoperative period. This is problematic since many of these old antiemetics have been used for decades, and they are still widely used in daily clinical practice. However, unless their relative efficacy is established, there cannot be evidence-based treatment recommendations for PONV. There is a plethora of randomised clinical trials on the prevention of PONV symptoms and a paucity of therapeutic trials, and there may be several reasons for this discrepancy. Therapeutic trials are logistically more difficult to perform. If the baseline risk of 30% vomiting and nauseous postoperative patients is about right, then of 1,000 patients who have given their informed consent to take part in a therapeutic trial, 300 may eventually suffer from PONV symptoms. Only these may then be randomised and treated, and need to be followed-up for 24 hours. Trialists may prefer to give a drug to all patients prophylactically, and then see what's happening. Also, manufacturers may have more commercial interest in prophylaxis strategies than in treatment strategies, since then all patients will receive the drug and not only those who actually need it. Most valid data came from large multicentre trials that have been designed and sponsored by the manufacturers of the modern 5-HT3 receptor antagonists. Most of these trials were laudable examples of placebo-controlled dose-finding studies. However, none of them compared two 5-HT3 receptor antagonists. And one only compared a 5-HT3 receptor antagonist with a classic antiemetic [36]. In that trial, ondansetron 4 mg was superior to metoclopramide 10 mg. Metoclopramide 10 mg, however, is not antiemetic [51].

It seems that manufacturers of old classic antiemetics are not interested in testing their compounds in well designed large trials; these drugs are widely used anyway despite the lack of evidence-based high-quality data. For none of these classic antiemetics, a dose-response has been established, and for none the optimal dose to treat established PONV is known. Manufacturers of the new compounds have produced high-quality data. However, they are not keen to compare their drugs with other new active comparators, or with effective regimens of old antiemetics. Also, in these trials, anti-nausea data are often underreported. This may lead to a false impression of antiemetic efficacy.

Conclusions

In postoperative patients who are suffering from nausea or vomiting, 5-HT3 receptor antagonist have some effect on vomiting and less so on nausea. Minimal effective doses should be used since these are as effective as much higher doses. There is a lack of valid data for the classic antiemetics. Evidence-based treatment strategies that take into account all possible antiemetic interventions have not yet been established [49]. If anaesthesiologists do not want to rely exclusively on drugs that are expensive and of limited anti-nausea efficacy they need to design valid trials with older classic antiemetics. Future trials should be randomised, properly double-blind, and placebo-controlled. They should report on both short (up to 6 hours after treatment) and long (to 24 hours) observation periods, although it would be useful to also report on the delay until the antiemetic treatment shows efficacy. Nausea and vomiting should be separately reported, and adverse drug reactions need to be documented.

Funding

Prosper Grant N° 3233–051939.97 from the Swiss National Research Foundation (MRT).

Competing Interests

None declared.

Pre-publication history

The pre-publication history for this paper can be accessed here: